2 research outputs found
Structure–Cytotoxicity Relationships of Analogues of <i>N</i><sup>14</sup>-Desacetoxytubulysin H
Herein
we report structure–cytotoxicity relationships for
analogues of <i>N</i><sup>14</sup>-desacetoxytubulyisn H <b>1</b>. A novel synthetic approach toward <b>1</b> enabled
the discovery of compounds with a range of activity. Calculated basicity
of the <i>N</i>-terminus of tubulysins was shown to be a
good predictor of cytotoxicity. The impact of structural modifications
at the C-terminus of <b>1</b> upon cytotoxicity is also described.
These findings will facilitate the development of new tubulysin analogues
for the treatment of cancer
Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)
A novel series of small-molecule
inhibitors has been developed
to target the double mutant form of the epidermal growth factor receptor
(EGFR) tyrosine kinase, which is resistant to treatment with gefitinib
and erlotinib. Our reported compounds also show selectivity over wild-type
EGFR. Guided by molecular modeling, this series was evolved to target
a cysteine residue in the ATP binding site via covalent bond formation
and demonstrates high levels of activity in cellular models of the
double mutant form of EGFR. In addition, these compounds show significant
activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to
their observed clinical efficacy. A glutathione (GSH)-based assay
was used to measure thiol reactivity toward the electrophilic functionality
of the inhibitor series, enabling both the identification of a suitable
reactivity window for their potency and the development of a reactivity
quantitative structure-property relationship (QSPR) to support design